BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
September 5, 2024 4:00 PM UTCSOUTH SAN FRANCISCO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, MD from September 8, 2024 September 10, 2024.
Title: A First-in-Human, Single & Multiple Ascending Dose Study of CK-4021586, A Novel Cardiac Myosin Inhibitor
Presenter: Justin Lutz, Pharm. D., Ph.D., Senior Director, Clinical Pharmacology, Cytokinetics
Date: September 8, 2024
Session Title: Opening Reception, Exhibits & Poster Session 1
Topic: Pharmacokinetics (Including PopPK, ADME,... More
